NASDAQ · Drug Manufacturers - Specialty & Generic
DERM (DERM) Stock
$6.31
-0.94%
NASDAQ: DERM
Healthcare
Valuation
Financials & Margins
Annual Financials (USD)
Balance Sheet (USD)
Latest News
Journey Medical (DERM) Stock Draws Fresh Price Target Split After Fortress Valuation Changes
Simply Wall St. · Jun 25, 2026
How The Journey Medical (DERM) Investment Narrative Is Evolving With An Unchanged Valuation Target
Simply Wall St. · Jun 3, 2026
Journey Medical Corporation to Participate in A.G.P.’s Annual Virtual Healthcare Conference
GlobeNewswire · May 19, 2026
Journey Medical Corporation Q1 2026 Earnings Call Summary
Moby · May 15, 2026
Journey Medical Corp (DERM) Q1 2026 Earnings Call Highlights: Revenue Growth and Strategic ...
GuruFocus.com · May 14, 2026
Cash Flow (USD)
Valuation & Return Ratios
Ownership
Insiders Held32.77%
Institutions Held59.20%
Institutions Float Held88.05%
Peer Comparison
About DERM
DERM is led by CEO Claude Maraoui, employs 41 people, headquartered in US, publicly traded since 2021.
DERM stock trades at $6.31 with a market capitalization of $173.66M. The stock is valued at a price-to-earnings (P/E) ratio of -13.53, price-to-book of 5.63, price-to-sales of 2.71. Over the past 52 weeks the stock has ranged between $4.31 and $9.55, and currently trades 34.0% below its 52-week high.
On profitability, DERM generates a return on equity (ROE) of -36.62%, return on capital employed of -25.00%, an operating margin of -9.80%, a net profit margin of -14.82%.